Up-regulation of S100P was reported in breast cancer, prostate cancer and early-stage non-small cell lung cancer [38-40], and it was also suggested to be a key factor in the aggressiveness of pancreatic cancer and promote cancer growth, survival and invasion [41]. Here, S100P is linked to prostate cancer.